R0908
R1881
≥98% (HPLC), Androgen receptor agonist, powder
別名:
(17b)-17-ヒドロキシ-17-メチル-エストラ-4,9,11-トリエン-3-オン, NSC 92858, RU 1881, メチルトリエノロン, メトリボロン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C19H24O2
CAS番号:
分子量:
284.39
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
製品名
R1881, ≥98% (HPLC)
SMILES string
C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@]12C
InChI key
CCCIJQPRIXGQOE-XWSJACJDSA-N
InChI
1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -48 to -68°
drug control
USDEA Schedule IIIN; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada
color
light yellow to yellow
solubility
DMSO: ≥10 mg/mL
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
R1881（メチルトリエノロン）は、強力な合成アンドロゲンです。
アンドロゲン受容体（AR）は、核内ホルモン受容体／転写因子です。 R1881は、メチルトリエノロンとしても知られている合成アンドロゲンです。ARアゴニストのゴールドスタンダードです。
Features and Benefits
本化合物は、Handbook of Receptor Classification and Signal Transductionの核内受容体（ステロイド）のページに掲載されています。ハンドブックのその他のページをご覧になるには、ここをクリックしてください。
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Robert S Hudson et al.
Molecular cancer, 12, 13-13 (2013-02-16)
Ultraconserved regions (UCR) are genomic segments of more than 200 base pairs that are evolutionarily conserved among mammalian species. They are thought to have functions as transcriptional enhancers and regulators of alternative splicing. Recently, it was shown that numerous RNAs
Annelies Van Hemelryk et al.
Biomolecules, 11(11) (2021-11-28)
Organoid-based studies have revolutionized in vitro preclinical research and hold great promise for the cancer research field, including prostate cancer (PCa). However, experimental variability in organoid drug testing complicates reproducibility. For example, we observed PCa organoids to be less affected
Nader Al Nakouzi et al.
European urology, 68(2), 228-235 (2014-05-20)
Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of
Juliet Richards et al.
Cancer research, 72(9), 2176-2182 (2012-03-14)
Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an antiandrogen. Abiraterone, a rationally designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC), is often effective
Lingyan Jin et al.
Cancer research, 77(20), 5564-5575 (2017-08-19)
Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here, we report that the transcriptional coactivator CBP/p300 is required to maintain the growth of castration-resistant prostate cancer. To
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）